AZD5153

CAT: 0804-HY-100653-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-100653-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
AZD5153 is a bivalent, selective, and orally active BET/BRD4 bromodomain inhibitor with an IC50 of value of 5 nM for full-length BRD4 (FL-BRD4) . AZD5153 ligates two bromodomains in BRD4 simultaneously. AZD5153 can be used for the study of cancer, such as acute myeloid leukemia, multiple myeloma, and diffuse large B-cell lymphoma[1].
CAS Number
[1869912-39-9]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/azd5153.html
Purity
99.20
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1N(C)CCN(CCOC2=CC=C(C3CCN(C4=NN5C(C=C4)=NN=C5OC)CC3)C=C2)[C@@H]1C
Molecular Formula
C25H33N7O3
Molecular Weight
479.57
Precautions
H302, H315, H319, H335
References & Citations
[1]Rhyasen GW, et al. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies. Mol Cancer Ther. 2016 Nov;15 (11) :2563-2574.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Citation 01
BioRxiv. 2025 Sep 3:2025.08.30.673282.|J Biomed Mater Res A. 2025 Apr;113 (4) :e37909.|J Med Chem. 2020 Jul 9;63 (13) :7186-7210.|Mol Cancer Ther. 2025 Jul 2.|Front Cell Dev Biol. 2022 Mar 24:10:853652.

Popular Products